Gemigliptin

DB12412InvestigationalSmall molecule

Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage hyperglycemia in patients with type 2 diabetes mellitus. Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

Chemical structure of Gemigliptin
Mechanism
Curator reviewed
Formula / weight
C18H19F8N5O2 · 489.37 g/mol (avg)
Code names
LC-15-0444

Resolves to

Compound
UNII5DHU18M5D6CAS911637-19-9ChEMBLCHEMBL3707235ChEBI134731PubChem11953153
Clinical / RWD
ATCA10BD18ATCA10BD30ATCA10BH06
Structure
InChIKeyZWPRRQZNBDYKLH-VIFPVBQESA-NSMILESN[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(C1)N=C(N=C2C(F)(F)F)C(F)(F)F
Targets
P27487DPP4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
657Drug interactionsStructured to mechanism, not free text
Sign in
27Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
4ATC codesIncluding every combination product, plus 8 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Gemigliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In